Literature DB >> 7150618

Resolution into two different forms and study of the properties of phosphatidylinositol-specific phospholipase C from human platelet cytosol.

L Y Chau, H H Tai.   

Abstract

Two forms of phosphatidylinositol-specific phospholipase C from human platelet cytosol were resolved by DEAE-cellulose chromatography and purified further by hydrophobic chromatography. Both forms utilized phosphatidylinositol as the best substrate. However, the enzyme did not distinguish 2-arachidonylphosphatidylinositol from 2-oleoylphosphatidylinositol although the former substrate was known to be a predominant species in human platelets. Both forms exhibited pH optimum at 7.0. Both activities were inhibited completely by 1 mM EDTA and the inhibited preparations could be restored to full activity or to 60% by free Ca2+ or Co2+, respectively, at 100 microM. Higher concentrations of either ion were inhibitory. Other metal ions were ineffective. Addition of calmodulin in the presence of Ca2+ did not show any additional effect. Both forms were inhibited comparably by various phospholipids, fatty acids and detergents, suggesting that phosphatidylinositol in membranes might be a poor substrate for the enzyme. Initiation of phosphatidylinositol breakdown through the phospholipase C pathway may require additional activator(s). A variety of anti-platelet drugs, including phenylthiazines, local anesthetics and mepacrine, were found to be potent inhibitors of the enzyme, suggesting that these drugs might inhibit platelet function by inhibiting the early phase of arachidonate release.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150618

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors.

Authors:  S Cockcroft; G M Thomas
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

2.  Characterization of phosphoinositide-specific phospholipase C from human platelets.

Authors:  V Manne; H F Kung
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

3.  Inositol phospholipid arachidonic acid metabolism in GH3 pituitary cells.

Authors:  D T Dudley; A A Spector
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

4.  Characterization of multiple forms of phosphoinositide-specific phospholipase C purified from human platelets.

Authors:  M G Low; R C Carroll; A C Cox
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

5.  Multiple forms of phosphoinositide-specific phospholipase C of different relative molecular masses in animal tissues. Evidence for modification of the platelet enzyme by Ca2+-dependent proteinase.

Authors:  M G Low; R C Carroll; W B Weglicki
Journal:  Biochem J       Date:  1984-08-01       Impact factor: 3.857

6.  Role of rap1B and p21ras GTPase-activating protein in the regulation of phospholipase C-gamma 1 in human platelets.

Authors:  M Torti; E G Lapetina
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  The effect of sn-2 fatty acid substitution on phospholipase C enzyme activities.

Authors:  J S Bomalaski; M A Clark
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

8.  Purification of two distinct types of phosphoinositide-specific phospholipase C from rat liver. Enzymological and structural studies.

Authors:  O Nakanishi; Y Homma; H Kawasaki; Y Emori; K Suzuki; T Takenawa
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

9.  Resolution of the phosphoinositide-specific phospholipase C isolated from porcine lymphocytes into multiple species. Partial purification of two isoenzymes.

Authors:  H R Carter; A D Smith
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

10.  Resolution of myocardial phospholipase C into several forms with distinct properties.

Authors:  M G Low; W B Weglicki
Journal:  Biochem J       Date:  1983-11-01       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.